Viruses, Vol. 13, Pages 654: Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy

Viruses, Vol. 13, Pages 654: Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy Viruses doi: 10.3390/v13040654 Authors: Kumar Giacomantonio Gujar Oncolytic reovirus preferentially targets and kills cancer cells via the process of oncolysis, and additionally drives clinically favorable antitumor T cell responses that form protective immunological memory against cancer relapse. This two-prong attack by reovirus on cancers constitutes the foundation of its use as an anticancer oncolytic agent. Unfortunately, the efficacy of these reovirus-driven antitumor effects is influenced by the highly suppressive tumor microenvironment (TME). In particular, the myeloid cell populations (e.g., myeloid-derived suppressive cells and tumor-associated macrophages) of highly immunosuppressive capacities within the TME not only affect oncolysis but also actively impair the functioning of reovirus-driven antitumor T cell immunity. Thus, myeloid cells within the TME play a critical role during the virotherapy, which, if properly understood, can identify novel therapeutic combination strategies potentiating the therapeutic efficacy of reovirus-based cancer therapy.
Source: Viruses - Category: Virology Authors: Tags: Review Source Type: research